文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

儿童噬血细胞性淋巴组织细胞增生症的遗传与机制多样性

Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.
PubMed 文献 · Blood · 2018-04-09

该研究纳入122例符合HLH-2004标准的儿童,其中101例接受基因检测,仅19例(19%)检出双等位基因家族性HLH基因缺陷,且与1岁前发病相关(P < .0001)。48例中28例(58%)经研究性全外显子测序发现可能的分子解释;总生存率为45%,感染或恶性肿瘤触发的HLH死亡率更高(P < .05)。作者认为HLH应被视为不同机制导致免疫细胞毒性激活的危重症表型,全外显子测序可能发现治疗机会并影响造血干细胞移植选择。

要点

  • 符合HLH-2004标准的儿童中仅19%检出双等位基因家族性HLH基因缺陷,且与1岁前发病相关(P < .0001)。
  • 48例中28例(58%)经研究性全外显子测序发现可能的分子解释,包括原发免疫缺陷病等。
  • 总生存率45%,感染或恶性肿瘤触发的HLH死亡率更高(P < .05),生存差异与遗传背景或治疗强度无关。

核心结论

  • HLH应被视为不同机制导致免疫细胞毒性激活的危重症表型。
  • 多数HLH患者仅靶向测序家族性HLH基因不足以识别致病机制,全外显子测序可能发现特定治疗机会并影响造血干细胞移植选择。

研究设计与样本

  • 研究纳入122例符合HLH-2004标准的儿童,17年间入组,其中101例接受临床或研究性全外显子测序基因检测。
  • 临床指标与基因组结果进行关联分析。

主要发现

  • 101例接受基因检测者中仅19例(19%)检出双等位基因家族性HLH基因缺陷,且与1岁前发病相关(P < .0001)。
  • 双基因家族性HLH变异可见,但缺乏疾病关联的统计学支持。
  • 48例中28例(58%)经研究性全外显子测序成功发现可能的分子解释,包括原发免疫缺陷病、免疫激活与增殖失调疾病及潜在新遗传病。
  • 符合HLH-2004标准的患者中三分之二有HLH基础病因,包括遗传缺陷、自身免疫和恶性肿瘤。
  • 总生存率为45%,感染或恶性肿瘤触发的HLH死亡率更高(P < .05);生存差异与遗传背景或治疗强度无关。

关键数值与推荐

  • HLH-2004标准用于诊断HLH,但存在误用担忧,可能导致部分患者治疗欠佳。
  • 双等位基因家族性HLH基因缺陷与1岁前发病相关(P < .0001)。
  • 感染或恶性肿瘤触发的HLH死亡率更高(P < .05)。

临床怎么用

  • 作者认为HLH应被视为不同机制导致免疫细胞毒性激活的危重症表型。
  • 作者指出多数HLH患者仅靶向测序家族性HLH基因不足以识别致病机制。
  • 作者认为全外显子测序可能发现特定治疗机会并影响造血干细胞移植选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The HLH-2004 criteria are used to diagnose hemophagocytic lymphohistiocytosis (HLH), yet concern exists for their misapplication, resulting in suboptimal treatment of some patients. We sought to define the genomic spectrum and associated outcomes of a diverse cohort of children who met the HLH-2004 criteria. Genetic testing was performed clinically or through research-based whole-exome sequencing. Clinical metrics were analyzed with respect to genomic results. Of 122 subjects enrolled over the course of 17 years, 101 subjects received genetic testing. Biallelic familial HLH (fHLH) gene defects were identified in only 19 (19%) and correlated with presentation at younger than 1 year of age (P < .0001). Digenic fHLH variants were observed but lacked statistical support for disease association. In 28 (58%) of 48 subjects, research whole-exome sequencing analyses successfully identified likely molecular explanations, including underlying primary immunodeficiency diseases, dysregulated immune activation and proliferation disorders, and potentially novel genetic conditions. Two-thirds of patients identified by the HLH-2004 criteria had underlying etiologies for HLH, including genetic defects, autoimmunity, and malignancy. Overall survival was 45%, and increased mortality correlated with HLH triggered by infection or malignancy (P < .05). Differences in survival did not correlate with genetic profile or extent of therapy. HLH should be conceptualized as a phenotype of critical illness characterized by toxic activation of immune cells from different underlying mechanisms. In most patients with HLH, targeted sequencing of fHLH genes remains insufficient for identifying pathogenic mechanisms. Whole-exome sequencing, however, may identify specific therapeutic opportunities and affect hematopoietic stem cell transplantation options for these patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018. PMID: 29632024. doi:10.1182/blood-2017-11-814244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。